Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results

Alnylam Pharmaceuticals (NASDAQ:ALNY) announced its earnings results on Thursday. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.61), Briefing.com reports. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 119.85%. The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the business earned ($0.65) EPS. The firm’s revenue for the quarter was up 84.9% compared to the same quarter last year.

Here are the key takeaways from Alnylam Pharmaceuticals’ conference call:

• GAAP profitability: Alnylam achieved GAAP profitability for full‑year 2025 and reported nearly $3.0 billion in combined net product revenues (81% YoY), with the AMVUTTRA ATTR‑CM launch cited as the primary driver.
• 2026 guidance and 2030 goals: The company reiterated 2026 combined product sales guidance of $4.9–$5.3 billion (TTR $4.4–$4.7B) and launched “Alnylam 2030” targets aiming for global TTR leadership, >25% revenue CAGR to 2030 and ~30% non‑GAAP operating margin through 2030.
• AMVUTTRA launch dynamics: Early U.S. uptake is strong—approaching parity with tafamidis in new starts and >90% payer first‑line coverage—however management flagged expected Q1 2026 headwinds from German pricing adjustments, seasonality and a mid‑single‑digit net price decline assumption.
• Pipeline and platform progress: Alnylam initiated three Phase‑3 trials (ZENITH for zilebesiran; TRITON‑CM and TRITON‑PN for nucresiran), added four new Alnylam clinical programs (e.g., ACVR1C and MAPT) and launched the Syrelis enzymatic ligation manufacturing platform to expand capacity and lower COGS.
• Near‑term financial headwinds: Gross margin declined to 77% in 2025 due to higher royalties (Sanofi), 2026 collaboration/royalty revenue guidance is down (no repeat of the $300M milestone), and the company anticipates continued net price pressure in the U.S.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $314.40 on Friday. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $495.55. The stock has a market cap of $41.54 billion, a P/E ratio of 183.86 and a beta of 0.35. The stock’s 50 day simple moving average is $374.98 and its 200 day simple moving average is $424.03. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49.

Wall Street Analyst Weigh In

A number of research firms have commented on ALNY. Barclays began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price target on the stock. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Wells Fargo & Company decreased their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Oppenheimer started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective for the company. Finally, Jefferies Financial Group reduced their price objective on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Twenty-two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $477.38.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total value of $848,055.70. Following the completion of the transaction, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $7,874,697.12. The trade was a 9.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the sale, the executive vice president directly owned 57,465 shares in the company, valued at $20,852,324.55. This represents a 4.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 31,305 shares of company stock worth $12,459,785 in the last 90 days. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ALNY. Prosight Management LP purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $6,803,000. FORA Capital LLC increased its stake in Alnylam Pharmaceuticals by 27.5% in the fourth quarter. FORA Capital LLC now owns 3,466 shares of the biopharmaceutical company’s stock valued at $1,378,000 after purchasing an additional 747 shares during the last quarter. Kestra Advisory Services LLC increased its stake in shares of Alnylam Pharmaceuticals by 12.5% during the 4th quarter. Kestra Advisory Services LLC now owns 1,851 shares of the biopharmaceutical company’s stock valued at $736,000 after acquiring an additional 206 shares during the last quarter. Transamerica Financial Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 11,076.6% during the 4th quarter. Transamerica Financial Advisors LLC now owns 8,606 shares of the biopharmaceutical company’s stock worth $3,422,000 after acquiring an additional 8,529 shares during the period. Finally, Marshall Wace LLP lifted its holdings in shares of Alnylam Pharmaceuticals by 8.2% during the 4th quarter. Marshall Wace LLP now owns 549,922 shares of the biopharmaceutical company’s stock worth $218,676,000 after acquiring an additional 41,551 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Amvuttra is powering large revenue gains and Alnylam reported full-year product revenues near $3B with strong year‑over‑year growth; the company also reported profitability for the first time — a clear fundamental positive for long‑term earnings potential. Business Wire: Alnylam Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Catalyst from analyst support — some firms (e.g., TD Cowen) are maintaining Buy ratings and framing Amvuttra as the catalyst for a longer‑term profitability inflection. TipRanks: Amvuttra-Driven Profitability Inflection Supports Buy Rating
• Neutral Sentiment: FY‑2026 revenue guidance was updated to roughly $5.3–$5.8B (slightly wide band vs. consensus), leaving mixed readthroughs for near‑term estimates and valuation models. Business Wire: FY‑2026 Guidance
• Neutral Sentiment: Analysts have trimmed price targets (e.g., Chardan, Needham) but many kept Buy ratings — this tempers upside expectations while still signaling continued institutional conviction. Benzinga: Analyst Price Target Changes
• Negative Sentiment: Market reaction to the Q4 release was mixed: some outlets flagged EPS and revenue misses vs. specific consensus numbers while others reported an EPS beat — the inconsistent takeaways have created volatility and investor uncertainty. Zacks: Q4 Earnings Beat, Sales Miss MarketBeat: Q4 Snapshot
• Negative Sentiment: Management signaled higher long‑term R&D/spend to fund pipeline ambitions and flagged execution/scaling risks for global Amvuttra rollout — comments that prompted some investors to downgrade longer‑term profit expectations. Seeking Alpha: Investors Revise Future Profit Expectations TipRanks: Execution Risks Loom
• Neutral Sentiment: Reported short‑interest figures in the feeds are effectively zero/placeholder and not informative for current positioning — ignore as a market signal until clearer data is posted.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.